Chemistry:RO-0282425
From HandWiki
RO-0282425 is a melanocortin MC4 receptor agonist which was under development for the treatment of erectile dysfunction but was never marketed.[1][2] Its route of administration was unspecified.[1] The drug was under development by Roche.[1][2] It reached phase 2 clinical trials by 2005 but its development was subsequently discontinued.[1][2] The chemical structure of RO-0282425, and whether it is a small molecule or a peptide, do not appear to have been disclosed.[1]
See also
References
 |  |
